Barrington raised the firm’s price target on HealthEquity (HQY) to $120 from $105 and keeps an Outperform rating on the shares ahead of the company reporting Q3 results on Monday, December 9, after market close. With a strong and “industry-leading” Health Savings Account business and a recovering consumer-directed benefits business, combined with a higher effective yield on cash for the next several years, the firm expects operating and financial performance to “continue to improve on a consolidated basis going forward,” the analyst tells investors in a preview.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HQY:
- HealthEquity price target raised to $118 from $95 at Jefferies
- HealthEquity initiated with a Neutral at Goldman Sachs
- HealthEquity price target raised to $130 from $110 at BTIG
- HealthEquity price target raised to $120 from $100 at BofA
- HealthEquity CEO Transition: Jon Kessler to Scott Cutler
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
